Physician profile
Christopher Cassisi
NPI 1528084183
$5,886.93
in general payments reported to CMS, 2019-2025
52 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $521 · 2021: $612 · 2022: $1,279 · 2023: $884 · 2024: $587 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.93 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $770.43 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Sumitomo Pharma America, INC. | $480.72 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $452.80 | 2019-2025 | Botox |
| Astellas Pharma US INC | $452.35 | 2019-2025 | Xtandi |
| Coloplast Corp | $435.70 | 2019-2023 | Titan |
| Pfizer INC. | $376.78 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $280.88 | 2019-2021 | |
| Antares Pharma, INC. | $205.39 | 2019-2024 | Xyosted |
| Myovant Sciences INC. | $202.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.53 | 2020-2023 | |
| Tolmar Pharmaceuticals, INC. | $161.38 | 2019-2022 | |
| Tolmar, INC. | $151.94 | 2023-2025 | Eligard, Jatenzo |
| Boston Scientific Corporation | $151.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $125.53 | 2022-2025 | |
| Comsort, INC | $100.00 | 2019 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cassisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.